<DOC>
	<DOCNO>NCT02579122</DOCNO>
	<brief_summary>In view fact little known pre- post-interventional coagulation management phenprocoumon patient reviparin general practice Germany , observational study initiate evaluate effectiveness tolerability reviparin area outpatient , general practice-based care context bridging therapy . Patients bridge therapy low-molecular weight heparin ( LMWH ) specify LMWH reviparin chosen purpose shall investigate .</brief_summary>
	<brief_title>REVIparin-BRIDging-in General Practice Setting GErmany</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Reviparin</mesh_term>
	<criteria>Patients &gt; 18 year old Requiring prophylaxis/bridging treatment reviparin , e.g . prevention venous thromboembolism general orthopaedic surgery , due decision treat physician Hypersensitivity reviparin one excipients ClivarinÂ® lowmolecularweight heparin preparation and/or heparin , e.g . confirm suspected immunemediated heparininduced thrombocytopenia ( type 2 ) Severe renal impairment ( creatinine clearance &lt; 30 ml/min ) Bleeding : like anticoagulant , reviparin use condition associate increase risk bleeding , e.g . acute bleeding , haemorrhagic diathesis , coagulation factor deficiency , severe thrombocytopenia , untreated arterial hypertension , bacterial endocarditis subacute endocarditis , acuteonset gastrointestinal ulcer haemorrhage , brain haemorrhage , spinal ear eye surgery , intraocular bleed correspond injury within past 6 month Severe hepatic pancreatic impairment Children Patients body weight &lt; 45kg Life expectancy le 3 month Pregnant woman ( due generally long duration treatment LMWH female patient already anticoagulation therapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Reviparin</keyword>
	<keyword>Bridging</keyword>
	<keyword>Phenprocoumon</keyword>
</DOC>